Bowman & Co S.C. Boosts Holdings in DexCom, Inc. (NASDAQ:DXCM)

Bowman & Co S.C. grew its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 9.8% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,924 shares of the medical device company’s stock after acquiring an additional 527 shares during the quarter. Bowman & Co S.C.’s holdings in DexCom were worth $672,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in DXCM. Capital World Investors raised its stake in shares of DexCom by 130.7% during the fourth quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock worth $1,151,392,000 after acquiring an additional 5,256,092 shares in the last quarter. Norges Bank purchased a new position in shares of DexCom in the fourth quarter worth $540,178,000. Artisan Partners Limited Partnership increased its stake in shares of DexCom by 164.8% in the fourth quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock worth $732,169,000 after buying an additional 3,672,471 shares during the period. Capital Research Global Investors increased its stake in shares of DexCom by 21.4% in the fourth quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock worth $1,898,085,000 after buying an additional 2,695,296 shares during the period. Finally, Massachusetts Financial Services Co. MA purchased a new position in shares of DexCom in the fourth quarter worth $231,773,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Michael Jon Brown sold 652 shares of the company’s stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $119.24, for a total value of $77,744.48. Following the transaction, the executive vice president now owns 67,560 shares in the company, valued at approximately $8,055,854.40. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other DexCom news, Director Bridgette P. Heller sold 1,000 shares of the business’s stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $113.55, for a total value of $113,550.00. Following the completion of the transaction, the director now owns 25,349 shares of the company’s stock, valued at approximately $2,878,378.95. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Michael Jon Brown sold 652 shares of the business’s stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $119.24, for a total value of $77,744.48. Following the completion of the transaction, the executive vice president now directly owns 67,560 shares of the company’s stock, valued at approximately $8,055,854.40. The disclosure for this sale can be found here. Insiders have sold a total of 4,135 shares of company stock worth $446,797 in the last quarter. Corporate insiders own 0.30% of the company’s stock.

DexCom Stock Up 2.5 %

Shares of DXCM stock traded up $1.79 during mid-day trading on Friday, reaching $74.07. 3,355,511 shares of the company’s stock traded hands, compared to its average volume of 3,779,422. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a market cap of $29.46 billion, a P/E ratio of 47.79, a P/E/G ratio of 2.18 and a beta of 1.16. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00. The company’s 50-day moving average price is $95.46 and its 200-day moving average price is $116.40.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. The company had revenue of $1 billion for the quarter, compared to analysts’ expectations of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. DexCom’s revenue was up 15.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.34 EPS. On average, equities analysts expect that DexCom, Inc. will post 1.69 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. UBS Group decreased their target price on shares of DexCom from $163.00 to $95.00 and set a “buy” rating on the stock in a research note on Friday, July 26th. Royal Bank of Canada decreased their target price on shares of DexCom from $165.00 to $145.00 and set an “outperform” rating on the stock in a research note on Friday, July 26th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $145.00 target price on shares of DexCom in a research note on Tuesday, July 23rd. Morgan Stanley reduced their price objective on shares of DexCom from $120.00 to $75.00 and set an “equal weight” rating on the stock in a research report on Friday, July 26th. Finally, Piper Sandler reduced their price objective on shares of DexCom from $150.00 to $90.00 and set an “overweight” rating on the stock in a research report on Friday, July 26th. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $112.25.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.